Form 8K Mink Therapeutics Inc For: 12 November
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mink Therapeutics Inc (INKT)
Mink Therapeutics Inc stock price live, this page displays NASDAQ INKT stock exchange data. View the INKT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mink Therapeutics Inc real time stock price chart below.
What Is the Mink Therapeutics Inc Stock Price Today?
The Mink Therapeutics Inc stock price today is 9.340.
What Is the Stock Symbol for Mink Therapeutics Inc?
The stock symbol for Mink Therapeutics Inc is "INKT."
What Stock Exchange Does Mink Therapeutics Inc Trade On?
Mink Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Mink Therapeutics Inc a Good Stock to Buy?
Determining whether Mink Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INKT quote. (ISIN: US6036932019)
What Is the Mink Therapeutics Inc Stock Price Today?
The Mink Therapeutics Inc stock price today is 9.340.
What Is the Stock Symbol for Mink Therapeutics Inc?
The stock symbol for Mink Therapeutics Inc is "INKT."
What Stock Exchange Does Mink Therapeutics Inc Trade On?
Mink Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Mink Therapeutics Inc a Good Stock to Buy?
Determining whether Mink Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INKT quote. (ISIN: US6036932019)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.000
9.680
52 wk Range
8.480
16.927
INKT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.0009.680
52 wk Range
8.48016.927
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INKT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
44.000
Upside
+371.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 44.000
(+371.09% Upside)
Mink Therapeutics Inc Earnings Call Summary for Q3/2026
- MiNK reported Q3 2026 loss of $0.50/share, beating analyst estimates of $0.63/share by 20.6%; revenue totaled $200K.
- Company confirmed 12-month cash runway of $9.5M to fund operations, including randomized phase II/III ARDS trial launch.
- Shares fell 2.77% to $10.01, unchanged after-hours, as investors await clinical data over financial results for validation.
- Management expects preliminary ARDS trial data in H2 2026; FDA meeting scheduled on trial design for lead therapy agenT-797.
- CEO Buell highlighted progress toward commercialization, addressing cell therapy barriers in manufacturing, scalability, and acute care use.
Last Updated: 2026-11-11, 09:30 a/m
Read Full TranscriptEarnings
Latest Release
Nov 11, 2026
EPS / Forecast
-0.50 / -0.63
Revenue / Forecast
200K / --
Compare INKT to Peers and Sector
Metrics to compare | INKT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINKTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −1.4x | −0.2x | |
PEG Ratio | −0.27 | −0.01 | 0.00 | |
Price/Book | −2.9x | −0.6x | 2.6x | |
Price / LTM Sales | 238.3x | 20.5x | 2.8x | |
Upside (Analyst Target) | 371.1% | 168.4% | 65.0% | |
Fair Value Upside | Unlock | 20.5% | 9.6% | Unlock |
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mink Therapeutics (INKT) Stock Price Today?
The Mink Therapeutics stock price today is 9.340 USD.
What Stock Exchange Does Mink Therapeutics Trade On?
Mink Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Mink Therapeutics?
The stock symbol for Mink Therapeutics is "INKT."
What Is the Mink Therapeutics Market Cap?
As of today, Mink Therapeutics market cap is 48.630M USD.
What Is Mink Therapeutics's Earnings Per Share (TTM)?
The Mink Therapeutics EPS (TTM) is -2.25.
When Is the Next Mink Therapeutics Earnings Date?
Mink Therapeutics will release its next earnings report on Mar 23, 2027.
From a Technical Analysis Perspective, Is INKT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Mink Therapeutics Stock Split?
Mink Therapeutics has split 1 times.
How Many Employees Does Mink Therapeutics Have?
Mink Therapeutics has 15 employees.
What is the current trading status of Mink Therapeutics (INKT)?
As of Nov 14, 2026, Mink Therapeutics (INKT) is trading at a price of 9.340 USD, with a previous close of 9.530 USD. The stock has fluctuated within a day range of 9.000 USD to 9.680 USD, while its 52-week range spans from 8.480 USD to 16.927 USD.
What Is Mink Therapeutics (INKT) Price Target According to Analysts?
The average 12-month price target for Mink Therapeutics is 44.000 USD, with a high estimate of 50 USD and a low estimate of 38 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +371.09% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.